Beta-amyloid (Aβ) is a 39-43 amino acid peptide generated by sequential cleavage of the amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase. The two predominant isoforms — Aβ40 and Aβ42 — differ by two C-terminal residues but have dramatically different aggregation propensities.

Overview

Beta-amyloid was first isolated from cerebrovascular amyloid deposits and senile plaques in Alzheimer's disease brain tissue by Glenner and Wong in 1984. The subsequent identification of APP mutations causing familial AD, combined with the discovery that all known familial AD mutations alter Aβ production or the Aβ42/Aβ40 ratio, led to the formulation of the amyloid cascade hypothesis — the dominant theoretical framework in AD research for over three decades. Hardy J & Higgins GA (1992) — Science 256, 184-185.

APP is a type I transmembrane protein expressed abundantly in neurons. It can be processed through two competing pathways: the non-amyloidogenic pathway (α-secretase cleavage within the Aβ domain, precluding Aβ generation and producing the neuroprotective fragment sAPPα) and the amyloidogenic pathway (β-secretase then γ-secretase cleavage, generating intact Aβ peptides). The balance between these pathways determines Aβ production levels and is influenced by APP trafficking, lipid raft association, and endosomal sorting — processes regulated in part by SORLA and retromer components.

Under normal physiology, Aβ is produced at low levels and cleared through multiple mechanisms including enzymatic degradation (neprilysin, insulin-degrading enzyme), glymphatic drainage, microglial phagocytosis (enhanced by TREM2 signaling), and transport across the blood-brain barrier. AD develops when the balance between Aβ production and clearance is disrupted, leading to accumulation and aggregation.

Mechanism of Action

APP Processing and Aβ Generation: β-secretase (BACE1) cleaves APP at the N-terminus of the Aβ domain, releasing soluble APPβ (sAPPβ) and generating a membrane-bound C-terminal fragment (CTFβ/C99). γ-Secretase — a presenilin-containing intramembrane protease complex — then cleaves C99 within the transmembrane domain, releasing Aβ peptides of varying length (predominantly Aβ40 and Aβ42) and the APP intracellular domain (AICD). The precision of γ-secretase cleavage determines the Aβ42/Aβ40 ratio, which is elevated by presenilin-1 (PSEN1) and presenilin-2 (PSEN2) mutations that cause familial AD. De Strooper B et al. (2012) — Nat. Rev. Neurosci. 13, 77-93.

Aggregation Cascade: Aβ monomers undergo a nucleation-dependent polymerization process: monomers → soluble oligomers → protofibrils → mature amyloid fibrils → insoluble plaques. The toxic oligomer hypothesis posits that soluble Aβ oligomers (dimers, trimers, and higher-order assemblies including Aβ*56 and globulomers), rather than insoluble plaques, are the primary neurotoxic species. Oligomers impair synaptic function by interacting with multiple neuronal receptors including PrPC, mGluR5, and the α7 nicotinic acetylcholine receptor. Selkoe DJ & Hardy J (2016) — EMBO Mol. Med. 8, 595-608.

Neuroinflammation: Aβ aggregates activate microglia through pattern recognition receptors (TLR2, TLR4, CD36, RAGE) and the NLRP3 inflammasome, triggering release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6). While initial microglial activation may be protective (phagocytic clearance of Aβ, enhanced by TREM2 signaling), chronic activation produces a sustained inflammatory state that exacerbates neurodegeneration. Aβ also activates the complement cascade, leading to synapse elimination ("synapse stripping") via complement-mediated microglial phagocytosis.

Tau Interaction: Aβ pathology is upstream of tau pathology in the amyloid cascade hypothesis. Aβ oligomers promote tau hyperphosphorylation through activation of kinases (GSK-3β, CDK5) and impairment of phosphatases (PP2A). Aβ-induced tau pathology may spread in a prion-like manner through connected neural circuits, amplifying neurodegeneration beyond regions of initial Aβ deposition.

Reconstitution Calculator

Research

Safety Profile

Beta-amyloid is an endogenous peptide; safety considerations relate primarily to anti-amyloid therapeutics. The principal safety concern with anti-Aβ immunotherapy is amyloid-related imaging abnormalities (ARIA), encompassing ARIA-E (vasogenic edema and sulcal effusions) and ARIA-H (microhemorrhages and superficial siderosis). ARIA-E occurs in 12-35% of patients depending on the antibody, is more frequent in APOE ε4 carriers (particularly homozygotes), and is usually asymptomatic but can cause headache, confusion, dizziness, or visual changes. Most ARIA-E cases resolve within 3-4 months. Rare serious events include symptomatic ARIA with cerebral edema requiring hospitalization, and macrohemorrhage. APOE genotyping before treatment initiation is recommended for risk stratification. BACE1 inhibitors, despite effectively reducing Aβ production, were associated with cognitive worsening and neuropsychiatric adverse events in Phase 3 trials (verubecestat, atabecestat), likely due to disruption of BACE1 cleavage of non-APP substrates critical for synaptic function.

Clinical Research Protocols

Anti-amyloid immunotherapy protocols:

Lecanemab (Leqembi): 10 mg/kg IV every 2 weeks. Brain MRI at baseline, prior to 5th, 7th, and 14th infusions (minimum) to monitor for ARIA. APOE genotyping recommended. Treatment continuation decisions based on clinical response and ARIA status. Subcutaneous formulation (720 mg weekly) under development.

Donanemab (Kisunla): 700 mg IV every 4 weeks for first 3 doses, then 1400 mg IV every 4 weeks. Treatment may be discontinued upon achieving amyloid negativity on PET (tau-based stopping criteria). Brain MRI monitoring schedule similar to lecanemab.

Biomarker Assessment: Diagnosis confirmation via amyloid PET imaging (florbetapir, florbetaben, flutemetamol) or CSF Aβ42/Aβ40 ratio (low ratio indicates brain amyloid deposition). Plasma p-tau217 and Aβ42/Aβ40 ratio emerging as screening biomarkers.

Pharmacokinetic Profile

Ongoing & Future Research

• Combination Immunotherapy: Trials combining anti-Aβ antibodies with anti-tau or anti-inflammatory agents to address multiple AD pathologies simultaneously.

• Prevention Trials: AHEAD 3-45 study testing lecanemab in cognitively normal individuals with elevated amyloid (A45) or intermediate amyloid levels (A3). DIAN-TU testing anti-Aβ antibodies in autosomal dominant AD mutation carriers years before expected symptom onset.

• Subcutaneous Formulations: Development of subcutaneous lecanemab and donanemab for at-home administration, improving treatment accessibility and reducing infusion burden.

• Gene Therapy Approaches: AAV-delivered anti-Aβ antibody genes or BACE1-targeting siRNA for sustained CNS Aβ reduction without repeated infusions.

• Blood-Brain Barrier Shuttle Technologies: Engineering anti-Aβ antibodies with transferrin receptor-binding domains for enhanced brain penetration, potentially reducing required doses and ARIA risk.

• Next-Generation Vaccines: Active immunization approaches targeting specific Aβ epitopes (N-terminal, mid-domain, pyroglutamate-modified) to generate sustained anti-Aβ antibody responses without the cost and infusion burden of passive immunotherapy.